Short-Acting B2 Agonists Market Report 2026
Download Free Sample Buy Now
Short-Acting B2 Agonists Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Short-Acting B2 Agonists Market Report 2026

Global Outlook – By Type (Albuterol, Levalbuterol, Metaproterenol, Other Types), By Indication (Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm), By Administration Route (Inhalation, Oral, Injection), By End User (Hospitals, Clinics, Home Healthcare Settings) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Short-Acting B2 Agonists Market Overview

• Short-Acting B2 Agonists market size has reached to $4.4 billion in 2025

• Expected to grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%

• Growth Driver: Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief

• Market Trend: Advancements In Inhaler Technology For Efficient Acute Symptom Management

• North America was the largest region in 2025.

What Is Covered Under Short-Acting B2 Agonists Market?

Short-acting beta-2 agonists are a class of medications commonly used to provide quick relief from symptoms of asthma and other respiratory conditions. These drugs work by stimulating beta-2 adrenergic receptors in the smooth muscle lining of the airways, leading to rapid bronchodilation or relaxation of the muscles around the airways.

The main short-acting b2 agonists type include albuterol, levalbuterol, metaproterenol, and others. Albuterol refers to a widely used short-acting B2 agonist that provides rapid relief from bronchospasm by relaxing airway muscles. It is used for asthama, chronic obstructive pulmonary disease (copd), and exercise-induced bronchospasm and can be administered through inhalation, oral, and injection routes. It is used by various end users such as hospitals, clinics, and home healthcare settings.

Short-Acting B2 Agonists Market Global Report 2026 Market Report bar graph

What Is The Short-Acting B2 Agonists Market Size and Share 2026?

The short-acting b2 agonists market size has grown steadily in recent years. It will grow from $4.4 billion in 2025 to $4.58 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to high asthma prevalence, emergency respiratory care needs, fast-acting bronchodilator demand, hospital-based treatment protocols, generic drug availability.

What Is The Short-Acting B2 Agonists Market Growth Forecast?

The short-acting b2 agonists market size is expected to see steady growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to air pollution increase, urban respiratory disease burden, growth in home inhaler use, pediatric asthma cases, outpatient respiratory care expansion. Major trends in the forecast period include continued use as first-line rescue medication, rising asthma and copd prevalence, preference for inhalation-based delivery, growth of homecare respiratory treatment, expansion of generic saba products.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Short-Acting B2 Agonists Market Segmentation

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Is The Driver Of The Short-Acting B2 Agonists Market?

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the short-acting B2 agonists market going forward. Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes breathing difficulties and reduced airflow, mainly due to prolonged exposure to harmful gases or cigarette smoke. The rise in chronic obstructive pulmonary disease (COPD) is due to increasing exposure to air pollution, as long-term inhalation of pollutants like particulate matter and toxic gases can harm lung tissue and accelerate the disease's development. Short-acting ß2-agonists (SABAs) are used in COPD to quickly relieve symptoms like shortness of breath by relaxing airway muscles. They act as rescue medications during flare-ups but are not meant for long-term control. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (COPD) projected that the cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Therefore, the increasing prevalence of chronic obstructive pulmonary disease will boost the growth of the short-acting B2 agonists industry.

Key Players In The Global Short-Acting B2 Agonists Market

Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Global Short-Acting B2 Agonists Market Trends and Insights

Major companies in the short-acting B2 agonists market are focusing on developing technologically advanced products, such as pressurized metered-dose inhalers (pMDI), to help manage acute symptoms efficiently. Pressurized metered-dose inhalers (pMDIs) are handheld devices that deliver a specific dose of medication to the lungs in aerosol form using a propellant-driven spray commonly used for treating respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation. It contains albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. This unique combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Short-Acting B2 Agonists Market?

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based manufacturer of short-acting B2 agonists, collaborated with Launch Therapeutics Inc. to help expedite Teva's ICS clinical research program-SABA (TEV-'248). With this collaboration, Teva Pharmaceutical Industries aims to accelerate the development and commercialization of its innovative dual-action asthma rescue inhaler to provide a more effective treatment option for adult and pediatric asthma patients. Launch Therapeutics Inc. is a US-based clinical development company.

Regional Insights

North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Short-Acting B2 Agonists Market?

The short-acting beta-2 agonists market consists of sales of nebulizer solutions, combination inhalers, respiratory monitoring devices, spacers and holding chambers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Short-Acting B2 Agonists Market Report 2026?

The short-acting b2 agonists market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting b2 agonists industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Short-Acting B2 Agonists Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $4.58 billion
Revenue Forecast In 2035 $5.39 billion
Growth Rate CAGR of 4.1% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Type, Indication, Administration Route, End User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limi
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Short-Acting B2 Agonists Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Short-Acting B2 Agonists Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Short-Acting B2 Agonists Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Short-Acting B2 Agonists Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Industry 4.0 & Intelligent Manufacturing

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Sustainability, Climate Tech & Circular Economy

4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Continued Use As First-Line Rescue Medication

4.2.2 Rising Asthma And COPD Prevalence

4.2.3 Preference For Inhalation-Based Delivery

4.2.4 Growth Of Homecare Respiratory Treatment

4.2.5 Expansion Of Generic SABA Products

5. Short-Acting B2 Agonists Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Clinics

5.3 Home Healthcare Settings

5.4 Pulmonology Centers

5.5 Emergency Care Units

6. Short-Acting B2 Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Short-Acting B2 Agonists Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Short-Acting B2 Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Short-Acting B2 Agonists Market Size, Comparisons And Growth Rate Analysis

7.3. Global Short-Acting B2 Agonists Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Short-Acting B2 Agonists Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Short-Acting B2 Agonists Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Short-Acting B2 Agonists Market Segmentation

9.1. Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Albuterol, Levalbuterol, Metaproterenol, Other Types

9.2. Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

9.3. Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhalation, Oral, Injection

9.4. Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Clinics, Home Healthcare Settings, Hospitals

9.5. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhalers, Nebulizers, Tablets, Syrups

9.6. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhalers, Nebulizers, Oral Solutions

9.7. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhalers, Syrups

9.8. Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Terbutaline, Pirbuterol, Salbutamol

10. Short-Acting B2 Agonists Market Regional And Country Analysis

10.1. Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Short-Acting B2 Agonists Market

11.1. Asia-Pacific Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Short-Acting B2 Agonists Market

12.1. China Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Short-Acting B2 Agonists Market

13.1. India Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Short-Acting B2 Agonists Market

14.1. Japan Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Short-Acting B2 Agonists Market

15.1. Australia Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Short-Acting B2 Agonists Market

16.1. Indonesia Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Short-Acting B2 Agonists Market

17.1. South Korea Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Short-Acting B2 Agonists Market

18.1. Taiwan Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Short-Acting B2 Agonists Market

19.1. South East Asia Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Short-Acting B2 Agonists Market

20.1. Western Europe Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Short-Acting B2 Agonists Market

21.1. UK Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Short-Acting B2 Agonists Market

22.1. Germany Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Short-Acting B2 Agonists Market

23.1. France Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Short-Acting B2 Agonists Market

24.1. Italy Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Short-Acting B2 Agonists Market

25.1. Spain Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Short-Acting B2 Agonists Market

26.1. Eastern Europe Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Short-Acting B2 Agonists Market

27.1. Russia Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Short-Acting B2 Agonists Market

28.1. North America Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Short-Acting B2 Agonists Market

29.1. USA Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Short-Acting B2 Agonists Market

30.1. Canada Short-Acting B2 Agonists Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Short-Acting B2 Agonists Market

31.1. South America Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Short-Acting B2 Agonists Market

32.1. Brazil Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Short-Acting B2 Agonists Market

33.1. Middle East Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Short-Acting B2 Agonists Market

34.1. Africa Short-Acting B2 Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Short-Acting B2 Agonists Market, Segmentation By Type, Segmentation By Indication, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Short-Acting B2 Agonists Market Regulatory and Investment Landscape

36. Short-Acting B2 Agonists Market Competitive Landscape And Company Profiles

36.1. Short-Acting B2 Agonists Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Short-Acting B2 Agonists Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Short-Acting B2 Agonists Market Company Profiles

36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Short-Acting B2 Agonists Market Other Major And Innovative Companies

Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

38. Global Short-Acting B2 Agonists Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Short-Acting B2 Agonists Market

40. Short-Acting B2 Agonists Market High Potential Countries, Segments and Strategies

40.1 Short-Acting B2 Agonists Market In 2030 - Countries Offering Most New Opportunities

40.2 Short-Acting B2 Agonists Market In 2030 - Segments Offering Most New Opportunities

40.3 Short-Acting B2 Agonists Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Short-Acting B2 Agonists Market, Overview Of Key Products - Product Examples
  • Table 2: Global Short-Acting B2 Agonists Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Short-Acting B2 Agonists Market, Supply Chain Analysis
  • Table 4: Global Short-Acting B2 Agonists Market, Major Raw Material Providers
  • Table 5: Global Short-Acting B2 Agonists Market, Major Resource Providers
  • Table 6: Global Short-Acting B2 Agonists Market, Major Manufacturers (Suppliers)
  • Table 7: Global Short-Acting B2 Agonists Market, Major Distributors And Channel Partners
  • Table 8: Global Short-Acting B2 Agonists Market, Key Technologies & Future Trends
  • Table 9: Global Short-Acting B2 Agonists Market, Major Trends
  • Table 10: Global Short-Acting B2 Agonists Market, Major End Users
  • Table 11: Global Short-Acting B2 Agonists Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Short-Acting B2 Agonists Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Short-Acting B2 Agonists Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Short-Acting B2 Agonists Market - TAM, US$ Billion, 2025
  • Table 15: Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Global Short-Acting B2 Agonists Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 98: Global Short-Acting B2 Agonists Market - Company Scoring Matrix
  • Table 99: AstraZeneca plc Financial Performance
  • Table 100: Novartis AG Financial Performance
  • Table 101: GlaxoSmithKline plc Financial Performance
  • Table 102: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 103: Apotex Inc. Financial Performance
  • Table 104: Global Short-Acting B2 Agonists Market, Competitive Benchmarking (In USD Billions)
  • Table 105: Global Short-Acting B2 Agonists Market, Competitive Dashboard
  • Table 106: Global Short-Acting B2 Agonists Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 107: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030
  • Table 108: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Table 109: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Administration Route, 2025 – 2030

List Of Figures

    Figure 1: Global Short-Acting B2 Agonists Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Short-Acting B2 Agonists Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Short-Acting B2 Agonists Market, Supply Chain Analysis
  • Figure 4: Global Short-Acting B2 Agonists Market, Major Raw Material Providers
  • Figure 5: Global Short-Acting B2 Agonists Market, Major Resource Providers
  • Figure 6: Global Short-Acting B2 Agonists Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Short-Acting B2 Agonists Market, Major Distributors And Channel Partners
  • Figure 8: Global Short-Acting B2 Agonists Market, Key Technologies & Future Trends
  • Figure 9: Global Short-Acting B2 Agonists Market, Major Trends
  • Figure 10: Global Short-Acting B2 Agonists Market, Major End Users
  • Figure 11: Global Short-Acting B2 Agonists Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Short-Acting B2 Agonists Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Short-Acting B2 Agonists Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Short-Acting B2 Agonists Market - TAM, US$ Billion, 2025
  • Figure 15: Global Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Short-Acting B2 Agonists Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Albuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Levalbuterol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Metaproterenol, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Short-Acting B2 Agonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Short-Acting B2 Agonists Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Short-Acting B2 Agonists Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Short-Acting B2 Agonists Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Short-Acting B2 Agonists Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Short-Acting B2 Agonists Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Global Short-Acting B2 Agonists Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 98: Global Short-Acting B2 Agonists Market - Company Scoring Matrix
  • Figure 99: AstraZeneca plc Financial Performance
  • Figure 100: Novartis AG Financial Performance
  • Figure 101: GlaxoSmithKline plc Financial Performance
  • Figure 102: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 103: Apotex Inc. Financial Performance
  • Figure 104: Global Short-Acting B2 Agonists Market, Competitive Benchmarking (In USD Billions)
  • Figure 105: Global Short-Acting B2 Agonists Market, Competitive Dashboard
  • Figure 106: Global Short-Acting B2 Agonists Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 107: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030
  • Figure 108: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Figure 109: Global, Short-Acting B2 Agonists Market Size Gain ($ Billion), Segmentation By Administration Route, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Dopamine Agonists Market Report 2026 - Global Outlook – By Product Type (Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists), By Route of Administration (Oral, Parenteral, Transdermal Patches), By Distribut...

Muscarinic Acetylcholine Receptor Market Report 2026 - Global Outlook – By Type (M1 Receptor, M4 Receptor, M5 Receptor, Other Types), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Spe...

GLP-1 Receptor Agonist Market Report 2026 - Global Outlook – By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgica...

Extended-Release Drugs Market Report 2026 - Global Outlook – By Type (Sustained Release Drug, Controlled Release Drug), By Mode (Over-The-Counter, Prescription), By Distribution Channel (Hospital Pharmacies, Retail Pharm...

Active Pharmaceutical Ingredients Market Report 2026 - Global Outlook – By Type (Innovative Active Pharmaceutical Ingredient (APIs), Generic Active Pharmaceutical Ingredient (APIs)), By Manufacturer (Captive Manufacturer...

Chemical Auxiliary Agents Market Report 2026 - Global Outlook – By Type (Dispersing Agents, Emulsifying Agents, Wetting Agents, Stabilizing Agents, Thickening And Rheology Modifiers, Binding Agents, Defoaming And Antifoa...

mTOR Inhibitors Market Report 2026 - Global Outlook – By Product Type (Rapamune, Afinitor, Torisel, Zortress, Other Product Types), By Indication (Oncology, Immunosuppressant, Organ Transplantation, Other Indications), B...

Small Molecule Active Pharmaceutical Ingredient Market Report 2026 - Global Outlook – By Type (Synthetic, Chemical, Biological), By Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Card...

Frequently Asked Questions

The Short-Acting B2 Agonists market was valued at $4.4 billion in 2025, increased to $4.58 billion in 2026, and is projected to reach $5.39 billion by 2030.

The global Short-Acting B2 Agonists market is expected to grow at a CAGR of 4.2% from 2026 to 2035 to reach $5.39 billion by 2035.

Some Key Players in the Short-Acting B2 Agonists market Include, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd. .

Major trend in this market includes: Advancements In Inhaler Technology For Efficient Acute Symptom Management. For further insights on this market. request a sample here

North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us